ENDRA Life Sciences
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $428 | $0 |
Gross Profit | -50 | -55 | 367 | -70 |
EBITDA | -2,180 | -2,724 | -1,396 | -3,058 |
EBIT | -2,230 | -2,780 | -1,457 | -3,129 |
Net Income | -2,229 | -2,775 | -1,459 | -3,100 |
Net Change In Cash | 0 | 0 | 428 | 0 |
Free Cash Flow | -2,072 | -2,171 | -2,181 | -2,598 |
Cash | 6,400 | 1,134 | 2,833 | 3,334 |
Basic Shares | 10,804 | 10,804 | 10,390 | 7,683 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -275 | -234 | -224 | -165 |
EBITDA | -10,245 | -12,923 | -11,315 | -11,327 |
EBIT | -10,520 | -13,157 | -11,539 | -11,493 |
Net Income | -10,060 | -13,200 | -11,189 | -11,966 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | 1,053 | |||
Free Cash Flow | -9,582 | -12,971 | -11,167 | -10,821 |
Cash | 2,833 | 4,889 | 9,461 | 7,227 |
Basic Shares | 9,037 | 2,891 | 2,046 | 959 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$4 |
2024-03-31 | -$0.26 |
2023-12-31 | -$0.05 |
2023-09-30 | -$0.40 |
